tkm-100201
Nucleic acidexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01518881)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- EbolavirusANTISENSE INHIBITOR
Ebolavirus antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tkm-100201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01518881 | Phase 1 | Jan 1, 2012 | Arbutus Biopharma Corporation, Department of Defense, PRACS |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arbutus Biopharma Corporation | For profit | 1 | 1 | 1 | 2012 |
| Department of Defense | Government | 1 | 0 | 1 | 2012 |
| PRACS | For profit | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1